Fig 1: Exosomes act as cell-to-cell communication vehicles influencing MCF7 cells following treatment with exosomes. (A) Internalization of exosomes from MDA-MB-231 cells was confirmed by the uptake of exosomes in recipient MCF7 cells by using PKH67 polylinker dye (white arrows highlight exosome in Z-stack image). (B) MCF7 cells treated with Kaiso-depleted exosomes showed low expression of Kaiso, CD47, and SIRPA, but high expression of THBS1. The statistical method used was one-way ANOVA. (C) Polarization of THP1 cells using exosomes from Kaiso-depleted cells was assessed to demonstrate the influence of exosomes as communication vehicles by observing the expression of M1 and M2 macrophage markers. (D) Consistent with sh-Kaiso xenograft tissues (Figure 4F), THP1 cells treated with exosomes from sh-Kaiso cells showed a high expression of CD86 and a low expression of CD206, a marker for M1 macrophages; in contrast, THP1 cells treated with exosomes from sh-Scr cells showed a low expression of CD86 and a high expression of CD206, a marker for M2 macrophages. The statistical method used was the two-tailed paired t test. (E,F) BMDM treated with sh-SCR and sh-Kaiso cells showed higher phagocytosis (white arrow indicates phagocytosis) of sh-kaiso cells as compared to sh-SCR cells. The statistical method used was the two-tailed paired t test.
Fig 2: TCGA data validate the increased expression of Kaiso and CD47, with decreased expression of THBS1 correlating with TNBC breast cancer patients and linked with AA race. (A) High expression of Kaiso, CD47, SIRPA, and low expression of THBS1 was correlated with Basal-like BRCA and ER-negative patients. (B) Kaiso, CD47, and SIRPA expressed highly in Basal like patients as compared to non-basal patients, whereas THBS1 expression was deceased in Basal like patients as compared to non-basal patients. (C) The higher level of protein for Kaiso, CD47, and SIRPA and lower level of THBS1 observed in BRCA TNBC samples as compared to other subtypes collected from the PANCAN RPPA dataset. (D) The higher level of protein for Kaiso, CD47, and SIRPA in AA patient samples as compared to other races. (E) TCGA survival analysis identified that a high level of combined Kaiso, CD47, and SIRPA with a low level of THBS1 (Red line) indicate even poorer patient survival in AA BRCA patients compared to a low level of combined Kaiso, CD47, and SIRPA with a high level of THBS1 (Dark blue line).
Fig 3: Status of programmed death ligand 1/programmed death 1 (PD-L1/PD-1) and CD47–signal regulatory protein alpha (SIRPα) axes and their clinical relevance in PDAC. (A) i–vi. Expression of PD-L1, CD47, and SIRPα assessed by immunohistochemistry analysis. i. Representative case with negative PD-L1 expression in the invasive front (IF). ii. PD-L1 expression in tumor cells and mononuclear inflammatory cells in the IF (ii). Diffused CD47 expression in the IF (iii) and the tumor center (TC) (iv). Inserts denote areas with positive CD47 immunostaining. v. Expression of SIRPα in the IF both in cancer glands (arrowheads) and in the surrounding stroma (arrows). vi. Cross section of peripheral nerve expressing SIRPa, which serves as an internal positive control. Scale bar: 100 μm. (B) Quantification of PD-L1 scoring. # strong tendency. Data are expressed as mean ± STDEV (N = 27, without neoadjuvant therapy; N = 14, received neoadjuvant chemotherapy). (C) Quantification of CD47 scoring. * p-value < 0.05. Data are expressed as mean ± STDEV (N = 27, without neoadjuvant therapy; N = 14, with neoadjuvant chemotherapy). (D) Kaplan–Meier survival curve on PD-L1 and CD47 mRNA status in PDAC demonstrates that elevated PD-L1 and CD47 expression is associated with poor survival (N = 177).
Fig 4: Kaiso directly regulates the expression of the tumor suppressor, THBS1. (A) Kaiso depletion resulted in significantly higher expression of THBS1 in exosomes from MDA-MB-231 cells, whereas the expression of CD47 and SIRPA was decreased. The statistical method used was the two-tailed paired t test. (B) As consistent with exosomes, both gene expression, and protein expression analysis revealed that Kaiso depletion resulted in a significantly high expression of THBS1 in MDA-MB-231 cells, whereas the expressions of CD47 and SIRPA were decreased. The statistical method used was the two-tailed paired t test. (C) Schematic illustration of the THBS1 promoter showing the Kaiso binding site on the CpG island. Two oligonucleotides were designed as CHIP primers from two different sites where Kaiso binds in a methylation-dependent manner. (D,E) CHIP experiments with MDA-MB-231 chromatin demonstrated that Kaiso binds to the methylated region of the THBS1 promoter and that 5-aza reversed the binding. Both PCR and gel electrophoresis confirmed the binding. Input, 1% input DNA; Positive, anti-RNA Polymerase II and Negative, normal mouse IgG; 5-aza, 5-aza-2′-deoxycytidine. The uncropped blots are shown in Supplementary File S1.
Fig 5: Kaiso depletion attenuates the growth of TNBC cells. (A) Kaiso-depleted MDA-MB-231 xenograft tumors (sh-Kaiso) showed delayed tumor onset (~4 weeks) and development compared to control MDA-MB-231 (sh-Scr) xenograft tumors, as demonstrated by time-course analysis of tumor volumes in nude mice. The statistical method used was the F test to compare variances between sh-Scr and sh-Kaiso groups (** statistically significant p < 0.01) (B) sh-Kaiso cells also developed smaller tumor sizes and reduced tumor weights as compared to sh-Scr cells. The statistical method used was the two-tailed paired t test. (C) IHC-stained images of xenograft tissues with Kaiso, CD47, and SIRPA antibodies showed a marked decrease in intensity but an increase in THBS1 in Kaiso-depleted (sh-Kaiso) tumor tissues. (D,E) Hematoxylin and eosin (H&E) staining showed significantly increased phagocytosis (green arrow showed phagocytosis) in sh-Kaiso xenograft tissues as compared to sh-Scr xenograft tissues. The statistical method used was the two-tailed paired t test. (F) Immunofluorescence images of xenograft tissues showed that sh-Kaiso tissues have a high intensity of CD86 and a low intensity of CD206, an M1 macrophage marker, whereas Kaiso control sh-Scr tissues had a low intensity of CD86 and a high intensity of CD206, an M2 macrophage marker.
Supplier Page from Abcam for Anti-SIRP alpha antibody